A comprehensive pan‐cancer study has revealed that TP53/RB1 co‐alteration is the most prevalent co‐occurring genetic alteration across diverse cancer types, with particularly high frequencies in small‐cell carcinomas, neuroendocrine carcinomas, and sarcomas (SARCs) [4]. This evidence concerns the gene TP53 and cancer.